A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of SHR-1501 in
combination with SHR-1316 in patients with advanced malignancies and to provide a recommended
dose (RP2D) for subsequent clinical studies.